Sign in Subscribe
Pharmaceutical industry

Vemurafenib Shows Improved Survival in Metastatic Melanoma Patients with BRAF V600 Mutations

Strategic Insights

— 1 min read

Genentech, a member of the Roche Group, announced that a Phase III study (BRIM3) demonstrated vemurafenib significantly improved overall survival in patients with previously untreated BRAF V600 mutation-positive metastatic melanoma compared to chemotherapy. The study showed a 63% reduction in the risk of death for patients who received vemurafenib versus those who received chemotherapy. Additionally, vemurafenib reduced the risk of disease progression by 74% compared to chemotherapy. The safety profile of vemurafenib was consistent with previous clinical studies.

Key Takeaways:

  • Vemurafenib, a BRAF-inhibitor, significantly improved overall survival in patients with previously untreated BRAF V600 mutation-positive metastatic melanoma compared to chemotherapy.
  • The risk of death was reduced by 63% for patients who received vemurafenib compared to those who received chemotherapy.
  • Vemurafenib reduced the risk of disease progression by 74% compared to chemotherapy.
  • The safety profile of vemurafenib was consistent with previous clinical studies.
  • Patients were enrolled in the study based on BRAF mutation status as determined by the cobas 4800 BRAF V600 Mutation Test.
  • Vemurafenib is a personalised investigational medicine designed to specifically inhibit the activity of the mutant BRAF protein found in approximately half of all cases of melanoma.
  • The study results were presented by Paul Chapman, MD, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 5, 2011.
  • Roche/Genentech is planning to initiate a global, multicentre Phase II study exploring the efficacy and safety profile of vemurafenib in patients with BRAF V600 mutation-positive metastatic melanoma that has spread to the brain.

Statistics:

  • 675 patients were enrolled in the BRIM3 study.
  • 63% reduction in the risk of death for patients who received vemurafenib compared to those who received chemotherapy.
  • 74% reduction in the risk of disease progression for patients who received vemurafenib compared to chemotherapy.
  • Approximately half of all cases of melanoma have the BRAF mutation.
  • Vemurafenib is a personalised investigational medicine designed to inhibit the activity of the mutant BRAF protein.

Sources:

  • Genentech press release, 5 June 2011.
  • "Trials That Set New Standards of Care", press briefing at the Annual Meeting of the American Society of Clinical Oncology (ASCO), 5 June 2011.
  • BRIM3 study (Study NO25026) protocol.

Read more